Table 1.

Baseline levels and percent changes in bone turnover markers with testosterone therapy according to the presence of T2D

	T2D	non-T2D	P value
CTX
Baseline (ng/mL)	0.25 ± 0.14	0.40 ± 0.20	<.0001
6 months (%)	–12.3 ± 70.7	–28.5 ± 27.6	.92
12 months (%)	7.4 ± 55.9	–7.5 ± 41.6	.49
18 months (%)	18.6 ± 69.2	1.2 ± 62.8	.20
Osteocalcin
Baseline (ng/mL)	5.15 ± 3.04	7.44 ± 5.10	.01
6 months (%)	14.8 ± 64.5	–15.0 ± 46.3	.10
12 months (%)	28.9 ± 107.1	–4.3 ± 81.8	<.05
18 months (%)	19.3 ± 78.1	–0.4 ± 87.8	<.001
Alkaline phosphatase	`
Baseline (IU/L)	82,2 ± 22.0	80.4 ± 21.0	.67
6 months (%)	–2.32 ± 46.0	–7.7 ± 14.7	.45
12 months (%)	–3.5 ± 29.5	–10.0 ± 16.5	.22
18 months (%)	12.0 ± 102.4	–12.4 ± 16.2	.18
Sclerostin
Baseline (ng/mL)	0.84 ± 0.22	0.81 ± 0.28	.49
6 months (%)	9.2 ± 35.3	–7.6 ± 29.6	<.05
12 months (%)	14.1 ± 41.9	0.2 ± 44.3	<.05
18 months (%)	6,4 ± 44.8	10.9 ± 47.0	.58

Values are reported as means ± SD. Significant P values are reported in bold.

Abbreviation: T2D, type 2 diabetes mellitus.